IL301276A - Novel human antibodies that bind to human CD3-epsilon - Google Patents

Novel human antibodies that bind to human CD3-epsilon

Info

Publication number
IL301276A
IL301276A IL301276A IL30127623A IL301276A IL 301276 A IL301276 A IL 301276A IL 301276 A IL301276 A IL 301276A IL 30127623 A IL30127623 A IL 30127623A IL 301276 A IL301276 A IL 301276A
Authority
IL
Israel
Prior art keywords
seq
amino acid
acid sequence
antibody
human
Prior art date
Application number
IL301276A
Other languages
English (en)
Hebrew (he)
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of IL301276A publication Critical patent/IL301276A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL301276A 2020-09-24 2021-09-22 Novel human antibodies that bind to human CD3-epsilon IL301276A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20197975 2020-09-24
PCT/EP2021/076052 WO2022063819A1 (en) 2020-09-24 2021-09-22 Novel human antibodies binding to human cd3 epsilon

Publications (1)

Publication Number Publication Date
IL301276A true IL301276A (en) 2023-05-01

Family

ID=72644112

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301276A IL301276A (en) 2020-09-24 2021-09-22 Novel human antibodies that bind to human CD3-epsilon

Country Status (9)

Country Link
US (1) US20230357398A1 (https=)
EP (1) EP4217391A1 (https=)
JP (1) JP7851303B2 (https=)
KR (1) KR20230074192A (https=)
CN (1) CN116209680A (https=)
AU (1) AU2021350342A1 (https=)
CA (1) CA3189473A1 (https=)
IL (1) IL301276A (https=)
WO (1) WO2022063819A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3227537A1 (en) 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules
JP2026502768A (ja) * 2022-10-25 2026-01-27 アブレクシス， エルエルシー 抗ｃｄ３抗体
WO2025003511A1 (en) 2023-06-30 2025-01-02 Morphosys Ag Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025036892A1 (en) 2023-08-14 2025-02-20 Morphosys Ag Cycat halfbody molecules comprising sterically occluding moieties
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
US6136599A (en) 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
US8367586B2 (en) 2010-11-19 2013-02-05 Morphosys Ag Collection and methods for its use
CA2861003C (en) 2012-01-13 2023-03-28 Julius-Maximilians-Universitat Wurzburg Dual antigen-induced bipartite functional complementation
CN106459201A (zh) * 2014-05-28 2017-02-22 豪夫迈·罗氏有限公司 结合人和食蟹猴CD3ε的抗体
WO2019034580A1 (en) 2017-08-14 2019-02-21 Morphosys Ag HUMANIZED ANTIBODIES FOR CD3
WO2020115115A1 (en) 2018-12-05 2020-06-11 Morphosys Ag Multispecific antigen-binding molecules

Also Published As

Publication number Publication date
CN116209680A (zh) 2023-06-02
AU2021350342A1 (en) 2023-03-09
KR20230074192A (ko) 2023-05-26
JP7851303B2 (ja) 2026-04-24
JP2023542209A (ja) 2023-10-05
WO2022063819A1 (en) 2022-03-31
US20230357398A1 (en) 2023-11-09
EP4217391A1 (en) 2023-08-02
CA3189473A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
US11472880B2 (en) Humanized antibodies for CD3
JP2023051968A (ja) 多重特異的ＮＫｐ４６結合タンパク質
JP2020018298A (ja) Ｃｌｄｎ１８．２及びｃｄ３に対する抗体コンストラクト
KR20220050971A (ko) 신규 항-cd39 항체
CN113880952A (zh) 自然杀伤细胞接合抗体融合构建体
CN110325209A (zh) 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
US20230357398A1 (en) Novel human antibodies binding to human cd3 epsilon
CN107921122A (zh) 与cd38结合的抗体治疗剂
JP2017520575A (ja) 二重特異的ヘテロ二量体ダイアボディおよびその使用
JP7596263B2 (ja) ４－１ｂｂ及び腫瘍関連抗原に結合する抗体構築物ならびにその使用
CN114981301B (zh) Pd1和vegfr2双结合剂
EP4155318A1 (en) Bispecific antibody and use thereof
CN120712284A (zh) 抗pd-1抗体抗原结合域和免疫偶联物
CA3228137A1 (en) Cldn18.2-targeting antibody, bispecific antibody and use thereof
CN117355540A (zh) 抗cd137抗体和使用方法
JP2023547662A (ja) Ｃｌｄｎ６及びｃｄ３に選択的に結合するポリペプチド構築物
US20250206819A1 (en) Deimmunized antibodies specific for cd3
CN111818972A (zh) 去免疫的抗erbb3抗体
CN111788229A (zh) Csf1r结合剂
CN114340668A (zh) 结合于cd38和cd3的异源二聚抗体
TWI894360B (zh) 抗tigit抗體及雙抗體和它們的應用
WO2025003511A1 (en) Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
HK40126767A (zh) 抗cd3抗体及其用途
EA051514B1 (ru) Полипептидные конструкции, селективно связывающиеся с cldn6 и cd3
HK40034204A (en) Nk cell engaging antibody fusion constructs